FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2301230890> ?p ?o ?g. }

• W2301230890 endingPage "666" @default.
• W2301230890 startingPage "655" @default.
• W2301230890 abstract "Essentials•Activated factor VII–antithrombin complex (FVIIa‐AT) in plasma may reflect tissue factor exposure.•FVIIa‐AT levels were assessed in an angiographically controlled coronary artery disease (CAD) cohort.•High FVIIa‐AT levels correlated with an increased thrombin generation.•High FVIIa‐AT levels were associated with a greater risk of mortality in patients with stable CAD.Summary: BackgroundPlasma concentration of activated factor VII (FVIIa)–antithrombin (AT) complex has been proposed as an indicator of intravascular exposure of tissue factor.ObjectivesThe aims of this observational study were to evaluate (i) FVIIa‐AT plasma concentration in subjects with or without coronary artery disease (CAD) and (ii) its association with mortality in a prospective cohort of patients with CAD.MethodsFVIIa‐AT levels were measured by elisa in 686 subjects with (n = 546) or without (n = 140) angiographically proven CAD. Subjects with acute coronary syndromes and those taking anticoagulant drugs at the time of enrollment were excluded. CAD patients were followed for total and cardiovascular mortality.ResultsThere was no difference in FVIIa‐AT levels between CAD (84.8 with 95% confidence interval [CI] 80.6–88.2 pmol L–1) and CAD‐free subjects (83.9 with 95% CI 76.7–92.8 pmol L–1). Within the CAD population, during a 64‐month median follow‐up, patients with FVIIa‐AT levels higher than the median value at baseline (≥ 79 pmol L–1) had a two‐fold greater risk of both total and cardiovascular mortality. Results were confirmed after adjustment for sex, age, the other predictors of mortality (hazard ratio for total mortality: 2.05 with 95% CI 1.22–3.45, hazard ratio for cardiovascular mortality 1.94 with 95% CI 1.01–3.73, with a slight improvement of C‐statistic over traditional risk factors), FVIIa levels, drug therapy at discharge, and even patients using all the usual medications for CAD treatment. High FVIIa‐AT levels also correlated with increased thrombin generation.ConclusionsThis preliminary study suggests that plasma concentration of FVIIa‐AT is a thrombophilic marker of total and cardiovascular mortality risk in patients with clinically stable CAD. Essentials•Activated factor VII–antithrombin complex (FVIIa‐AT) in plasma may reflect tissue factor exposure.•FVIIa‐AT levels were assessed in an angiographically controlled coronary artery disease (CAD) cohort.•High FVIIa‐AT levels correlated with an increased thrombin generation.•High FVIIa‐AT levels were associated with a greater risk of mortality in patients with stable CAD. •Activated factor VII–antithrombin complex (FVIIa‐AT) in plasma may reflect tissue factor exposure.•FVIIa‐AT levels were assessed in an angiographically controlled coronary artery disease (CAD) cohort.•High FVIIa‐AT levels correlated with an increased thrombin generation.•High FVIIa‐AT levels were associated with a greater risk of mortality in patients with stable CAD. Plasma concentration of activated factor VII (FVIIa)–antithrombin (AT) complex has been proposed as an indicator of intravascular exposure of tissue factor. The aims of this observational study were to evaluate (i) FVIIa‐AT plasma concentration in subjects with or without coronary artery disease (CAD) and (ii) its association with mortality in a prospective cohort of patients with CAD. FVIIa‐AT levels were measured by elisa in 686 subjects with (n = 546) or without (n = 140) angiographically proven CAD. Subjects with acute coronary syndromes and those taking anticoagulant drugs at the time of enrollment were excluded. CAD patients were followed for total and cardiovascular mortality. There was no difference in FVIIa‐AT levels between CAD (84.8 with 95% confidence interval [CI] 80.6–88.2 pmol L–1) and CAD‐free subjects (83.9 with 95% CI 76.7–92.8 pmol L–1). Within the CAD population, during a 64‐month median follow‐up, patients with FVIIa‐AT levels higher than the median value at baseline (≥ 79 pmol L–1) had a two‐fold greater risk of both total and cardiovascular mortality. Results were confirmed after adjustment for sex, age, the other predictors of mortality (hazard ratio for total mortality: 2.05 with 95% CI 1.22–3.45, hazard ratio for cardiovascular mortality 1.94 with 95% CI 1.01–3.73, with a slight improvement of C‐statistic over traditional risk factors), FVIIa levels, drug therapy at discharge, and even patients using all the usual medications for CAD treatment. High FVIIa‐AT levels also correlated with increased thrombin generation. This preliminary study suggests that plasma concentration of FVIIa‐AT is a thrombophilic marker of total and cardiovascular mortality risk in patients with clinically stable CAD." @default.
• W2301230890 created "2016-06-24" @default.
• W2301230890 creator A5002162807 @default.
• W2301230890 creator A5003077821 @default.
• W2301230890 creator A5019733663 @default.
• W2301230890 creator A5023996952 @default.
• W2301230890 creator A5036886312 @default.
• W2301230890 creator A5038797557 @default.
• W2301230890 creator A5054468912 @default.
• W2301230890 creator A5057403590 @default.
• W2301230890 creator A5057583815 @default.
• W2301230890 creator A5060145568 @default.
• W2301230890 creator A5073992585 @default.
• W2301230890 creator A5085049981 @default.
• W2301230890 date "2016-04-01" @default.
• W2301230890 modified "2023-09-28" @default.
• W2301230890 title "Activated factor VII–antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study" @default.
• W2301230890 cites W1544456416 @default.
• W2301230890 cites W1609483177 @default.
• W2301230890 cites W1841869659 @default.
• W2301230890 cites W1964419071 @default.
• W2301230890 cites W1969327353 @default.
• W2301230890 cites W1970015059 @default.
• W2301230890 cites W1970516435 @default.
• W2301230890 cites W1974840145 @default.
• W2301230890 cites W1976114496 @default.
• W2301230890 cites W1977588361 @default.
• W2301230890 cites W1978049330 @default.
• W2301230890 cites W1989189156 @default.
• W2301230890 cites W2016404564 @default.
• W2301230890 cites W2024439562 @default.
• W2301230890 cites W2032602488 @default.
• W2301230890 cites W2035589437 @default.
• W2301230890 cites W2036767052 @default.
• W2301230890 cites W2044486816 @default.
• W2301230890 cites W2051174896 @default.
• W2301230890 cites W2054110881 @default.
• W2301230890 cites W2055864845 @default.
• W2301230890 cites W2068886931 @default.
• W2301230890 cites W2075728882 @default.
• W2301230890 cites W2088655909 @default.
• W2301230890 cites W2097530615 @default.
• W2301230890 cites W2099178721 @default.
• W2301230890 cites W2106129122 @default.
• W2301230890 cites W2106421416 @default.
• W2301230890 cites W2106597074 @default.
• W2301230890 cites W2113676816 @default.
• W2301230890 cites W2115470275 @default.
• W2301230890 cites W2120439472 @default.
• W2301230890 cites W2120579447 @default.
• W2301230890 cites W2122209028 @default.
• W2301230890 cites W2134843796 @default.
• W2301230890 cites W2144107403 @default.
• W2301230890 cites W2144939065 @default.
• W2301230890 cites W2146933358 @default.
• W2301230890 cites W2155065587 @default.
• W2301230890 cites W2158479730 @default.
• W2301230890 cites W2158859453 @default.
• W2301230890 cites W4292172722 @default.
• W2301230890 cites W4322700971 @default.
• W2301230890 doi "https://doi.org/10.1111/jth.13274" @default.
• W2301230890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27061056" @default.
• W2301230890 hasPublicationYear "2016" @default.
• W2301230890 type Work @default.
• W2301230890 sameAs 2301230890 @default.
• W2301230890 citedByCount "18" @default.
• W2301230890 countsByYear W23012308902017 @default.
• W2301230890 countsByYear W23012308902018 @default.
• W2301230890 countsByYear W23012308902019 @default.
• W2301230890 countsByYear W23012308902020 @default.
• W2301230890 countsByYear W23012308902021 @default.
• W2301230890 countsByYear W23012308902022 @default.
• W2301230890 crossrefType "journal-article" @default.
• W2301230890 hasAuthorship W2301230890A5002162807 @default.
• W2301230890 hasAuthorship W2301230890A5003077821 @default.
• W2301230890 hasAuthorship W2301230890A5019733663 @default.
• W2301230890 hasAuthorship W2301230890A5023996952 @default.
• W2301230890 hasAuthorship W2301230890A5036886312 @default.
• W2301230890 hasAuthorship W2301230890A5038797557 @default.
• W2301230890 hasAuthorship W2301230890A5054468912 @default.
• W2301230890 hasAuthorship W2301230890A5057403590 @default.
• W2301230890 hasAuthorship W2301230890A5057583815 @default.
• W2301230890 hasAuthorship W2301230890A5060145568 @default.
• W2301230890 hasAuthorship W2301230890A5073992585 @default.
• W2301230890 hasAuthorship W2301230890A5085049981 @default.
• W2301230890 hasBestOaLocation W23012308901 @default.
• W2301230890 hasConcept C126322002 @default.
• W2301230890 hasConcept C141071460 @default.
• W2301230890 hasConcept C164705383 @default.
• W2301230890 hasConcept C188816634 @default.
• W2301230890 hasConcept C201903717 @default.
• W2301230890 hasConcept C207103383 @default.
• W2301230890 hasConcept C2777557582 @default.
• W2301230890 hasConcept C2778213512 @default.
• W2301230890 hasConcept C2779026020 @default.
• W2301230890 hasConcept C2908647359 @default.
• W2301230890 hasConcept C44249647 @default.
• W2301230890 hasConcept C50440223 @default.

• next